Beriplex® P/N (Kcentra); Fresh frozen plasma
Проводит СиЭсЭл Беринг ГмбХ
Страница компанииAn Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00803101/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 176 чел. во всех странах исследования.
- Плановая дата окончания (02.2013) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 30
Критерии включения
- Male and female subjects greater than or equal to 18 years,
- Subjects currently on oral vitamin K antagonist (VKA) therapy,
- An urgent surgical procedure is required within 24 hours of the start of investigational medicinal product (IMP),
- Due to the nature of the procedure, withdrawal of oral VKA therapy and infusion of plasma are also indicated to reverse the VKA effect,
- INR greater than or equal to 2 within 3 hours before start of IMP,
- Informed consent has been obtained.
Критерии невключения
- Subjects requiring urgent surgical procedures where according to the surgeon's clinical judgment, an accurate estimate of blood loss is not possible (e.g., ruptured aneurysm),
- Subjects for whom administration of intravenous vitamin K and vitamin K antagonists withdrawal alone can adequately correct the subject's coagulopathy before initiation of the urgent surgical procedure,
- Administration of intravenous vitamin K more than 3 hours or administration of oral vitamin K more than 6 hours prior to infusion of IMP,
- Subjects in whom lowering INR within normal range may present an unacceptable risk for a thromboembolic complication where the INR goal is to lower but not normalize the INR because of risk of a procedure-associated stroke,
- Subjects, who despite medical management that includes close monitoring and diuretics, may not, by investigator assessment, tolerate the total volume of IMP required by the protocol,
- Expected need for additional non-study blood products before infusion of IMP (Note: Administration of packed red blood cells is not an exclusion criterion),
- Expected need for platelet transfusions or desmopressin before Day 10,
- Acute trauma for which reversal of vitamin K antagonists alone would not be expected to control or resolve an acute bleeding complication and/or control the acute bleeding event,
- Unfractionated or low molecular weight heparin use within 24 hours before randomization or potential need before completion of the procedure,
- History of thromboembolic event, myocardial infarction, unstable angina pectoris, critical aortic stenosis, cerebral vascular accident, transient ischemic attack, severe peripheral vascular disease, disseminated intravascular coagulation within 3 months of enrollment,
- Reversal of VKA therapy alone may not resolve the coagulopathy (eg, receiving a potent anti-platelet agent, i.e., clopidogrel or prasugrel, or advanced liver disease),
- Known history of antiphospholipid antibody syndrome or lupus anticoagulant antibodies,
- Suspected or confirmed serious viral or bacterial infection, e.g., meningitis, or sepsis at time of enrollment,
- Administration of whole blood, plasma, plasma fractions or platelets within 2 weeks prior to inclusion into the study (Note: Administration of packed red blood cells is not an exclusion criterion),
- Pre-existing progressive fatal disease with a life expectancy of less than 2 months,
- Known inhibitors to coagulation factors II, VII, IX, or X; or hereditary protein C or protein S deficiency; or heparin-induced, type II thrombocytopenia,
- Treatment with any other investigational medicinal product within 30 days prior to inclusion into the study,
- Presence or history of hypersensitivity to components of the study medication,
- Pregnant or breast-feeding women,
- Prior inclusion in this study or any other CSL Behring sponsored Beriplex study,
- For subjects with intracranial hemorrhage with:
- Glasgow Coma Score <10 (see Appendix 8)
- Modified Rankin Score > 3 prior to ICH (see Appendix 9)
- Intracerebral hemorrhage
- Epidural hematomas
- Infratentorial hemorrhage
- Subarachnoid hemorrhage (SAH) subjects with a Hunt and Hess Scale >2
- Subdural hematomas that:
- are judged to be an acute subdural hematoma (based on neurosurgeon review)
- have a concurrent SAH or parenchymal contusion
Источник: ClinicalTrials.gov, NCT00803101 · запись обновлена в реестре 6 апреля 2015.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 5
- Percentage of Participants Achieving Hemostatic Efficacy During Surgery — From the start of infusion until the end of surgery
- Percentage of Participants Who Had a Rapid Decrease of the INR — 30 minutes after the end of infusion
Цель исследования
The purpose of this study is to evaluate efficacy, safety and tolerance of Beriplex® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by vitamin K antagonists in subjects who require immediate correction of international normalized ratio (INR) because of emergency surgery.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00803101 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.